Pages that link to "Q37710498"
Jump to navigation
Jump to search
The following pages link to Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing (Q37710498):
Displaying 42 items.
- Quantitative Imaging Approaches to Study the CAR Immunological Synapse. (Q39405625) (← links)
- The Affinity of Elongated Membrane-Tethered Ligands Determines Potency of T Cell Receptor Triggering. (Q40964647) (← links)
- An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors (Q41252003) (← links)
- T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics (Q47570404) (← links)
- Advances in immunotherapy for pediatric acute myeloid leukemia (Q47930962) (← links)
- Redirecting T cells to hematological malignancies with bispecific antibodies. (Q48339827) (← links)
- Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies. (Q49951608) (← links)
- Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy (Q56890857) (← links)
- Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens (Q56891909) (← links)
- p95HER2-T cell bispecific antibody for breast cancer treatment (Q57042030) (← links)
- High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies (Q57281213) (← links)
- Immune Checkpoints as Therapeutic Targets in Autoimmunity (Q57817465) (← links)
- Full control of ligand positioning reveals spatial thresholds for T cell receptor triggering (Q57961679) (← links)
- Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety (Q58617435) (← links)
- Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies (Q58724935) (← links)
- Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents (Q58726545) (← links)
- Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1 (Q58790080) (← links)
- Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update (Q60909519) (← links)
- Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma (Q61799688) (← links)
- Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. (Q64988615) (← links)
- Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1 (Q88909913) (← links)
- A T CELL REDIRECTING BISPECIFIC G-PROTEIN COUPLED RECEPTOR CLASS 5 MEMBER DxCD3 ANTIBODY TO TREAT MULTIPLE MYELOMA (Q89629384) (← links)
- Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice (Q89721569) (← links)
- Engineering T cells for immunotherapy of primary human hepatocellular carcinoma (Q89848312) (← links)
- A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia (Q90160289) (← links)
- Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells (Q90212066) (← links)
- Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma (Q90241569) (← links)
- Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies (Q90244241) (← links)
- Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors (Q90454664) (← links)
- Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties (Q90496208) (← links)
- Molecular Interaction Characterization Strategies for the Development of New Biotherapeutic Antibody Modalities (Q90692927) (← links)
- Characterization of a Novel Bispecific Antibody That Activates T Cells In Vitro and Slows Tumor Growth In Vivo (Q91874492) (← links)
- Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules (Q92203166) (← links)
- Bispecific antibodies: a mechanistic review of the pipeline (Q92596473) (← links)
- An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity (Q92937464) (← links)
- DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing (Q92940332) (← links)
- Influence of the bispecific antibody IgG subclass on T cell redirection (Q93045072) (← links)
- Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy (Q93054897) (← links)
- Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions (Q94545332) (← links)
- Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics (Q94562689) (← links)
- Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies (Q95840982) (← links)
- Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing (Q101136377) (← links)